Cesca Therapeutics Reports Fourth Quarter and Fiscal 2016 Year End Results
September 20, 2016 16:57 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported fourth quarter and full...
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells
September 19, 2016 06:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States...
Cesca Therapeutics to Report Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update
September 16, 2016 06:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Sept. 16, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report...
Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw® Global Investment Conference
September 08, 2016 13:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Michael Bruch,...
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity
August 24, 2016 21:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has...
Cesca Therapeutics Announces Pricing of $2.5 Million Registered Direct Offering
August 04, 2016 09:07 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it has entered into...
Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study
August 03, 2016 06:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced 40-month follow-up...
Cesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of Non-Union Fracture
August 02, 2016 06:00 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that data for its...
Cesca Therapeutics Provides Update on FDA Review of Investigational Device Exemption Supplement for SurgWerks™ CLI Pivotal Trial
August 01, 2016 06:00 ET
|
Cesca Therapeutics Inc.
FDA Approves Commencement of Phase III Pivotal Trial as Amended Requires Additional Validation of TcPO2 as a Surrogate to Support Subsequent PMA Approval RANCHO CORDOVA, Calif., Aug. 01,...
Cesca Therapeutics Appoints Mark Bagnall to Its Board of Directors
June 20, 2016 06:05 ET
|
Cesca Therapeutics Inc.
RANCHO CORDOVA, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Mark Bagnall has...